198 related articles for article (PubMed ID: 29784848)
1.
Shoen C; DeStefano M; Hafkin B; Cynamon M
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784848
[TBL] [Abstract][Full Text] [Related]
2. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
Yang M; Zhan S; Fu L; Wang Y; Zhang P; Deng G
Drug Discov Ther; 2022 May; 16(2):99-101. PubMed ID: 35418550
[TBL] [Abstract][Full Text] [Related]
3. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
4. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
[TBL] [Abstract][Full Text] [Related]
5. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
6. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
7. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice.
Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S
Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
Yang C; Lei H; Wang D; Meng X; He J; Tong A; Zhu L; Jiang Y; Dong M
Jpn J Infect Dis; 2012; 65(3):240-2. PubMed ID: 22627306
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Huang TS; Liu YC; Sy CL; Chen YS; Tu HZ; Chen BC
Antimicrob Agents Chemother; 2008 Jun; 52(6):2226-7. PubMed ID: 18391030
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
12. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
Vilchèze C; Kim J; Jacobs WR
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
[TBL] [Abstract][Full Text] [Related]
13. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
Zou L; Liu M; Wang Y; Lu J; Pang Y
Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.
Alcalá L; Ruiz-Serrano MJ; Pérez-Fernández Turégano C; García De Viedma D; Díaz-Infantes M; Marín-Arriaza M; Bouza E
Antimicrob Agents Chemother; 2003 Jan; 47(1):416-7. PubMed ID: 12499228
[TBL] [Abstract][Full Text] [Related]
15. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of tedizolid and linezolid against multidrug-resistant Mycobacterium tuberculosis: a comparative study using microdilution broth assay and genomics.
Aono A; Murase Y; Chikamatsu K; Igarashi Y; Shimomura Y; Hosoya M; Osugi A; Morishige Y; Takaki A; Yamada H; Mitarai S
Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115714. PubMed ID: 35596983
[TBL] [Abstract][Full Text] [Related]
18. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Richter E; Rüsch-Gerdes S; Hillemann D
Antimicrob Agents Chemother; 2007 Apr; 51(4):1534-6. PubMed ID: 17242139
[TBL] [Abstract][Full Text] [Related]
19. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
20. Does linezolid have a role in shortening treatment of tuberculosis?
Yew WW; Chan DP; Chang KC
Clin Microbiol Infect; 2019 Sep; 25(9):1060-1062. PubMed ID: 31238119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
